The San Diego Union-Tribune looks at a roster of drug developers that are tweaking existing therapies and charging a premium compared to comparable generics. Case in point: Santarus' Zegerid, a heartburn medication that combines a generic ingredient with sodium bicarbonate. Critics contend that these "me-too" drugs simply waste billions of dollars and create a bad reputation for the biotech business, which prides itself on making critical advances that demand high-dollar returns to encourage expensive research.

- see this article [1] from the San Diego Union-Tribune for more